Haleon Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
This Haleon Value Chain Analysis gives a clear breakdown of how Haleon creates value through its support and primary activities, making it useful for research, strategy, investing, and business planning. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Haleon's firm infrastructure links global finance, legal, quality, and risk controls so a consumer-health pure play can keep science-backed brands trusted across more than 170 markets. In FY2024, Haleon reported £11.2 billion in revenue and £2.3 billion in adjusted operating profit, showing how disciplined governance supports capital allocation and portfolio choices. This backbone also helps Haleon keep cross-border standards tight while it manages regulated products, supply risk, and compliance costs.
In FY2025, Haleon reported about £11.0bn in net revenue, so human resource management is a scale issue, not a back-office task. It needs scientists, regulatory specialists, plant operators, supply-chain planners, and consumer-health commercial teams to keep the business moving.
Training in GMP, claims substantiation, and product safety protects execution across Haleon's 4 major health areas and lowers launch risk. Strong talent management also keeps brand and product-improvement know-how inside the business.
In FY2025, Haleon reported net revenue of about £11.2 billion, and its technology development work helped support that scale through formulation, clinical and consumer evidence, packaging, and digital analytics. These capabilities strengthen claims for Oral Health, Pain Relief, Respiratory Health, and Vitamins, Minerals and Supplements, while also speeding product refreshes and e-commerce readiness. One practical result is faster innovation cycles and better proof for science-backed brands.
Procurement
Haleon procures active ingredients, excipients, packaging, and selected manufacturing services from a broad global supplier base. Rigorous supplier qualification protects quality and supply continuity for everyday health products sold in over 100 markets. Large-scale buying also helps Haleon control input costs and defend margins when raw-material prices move.
Haleon's support activities keep a large consumer-health model tight: governance, talent, R&D, and sourcing all protect quality, claims, and margins. In FY2025, Haleon reported about £11.2 billion in net revenue, so these functions matter at scale. Supplier control and product evidence help support Oral Health, Pain Relief, Respiratory Health, and VMS across 170+ markets.
| Support activity | FY2025 signal |
|---|---|
| All support activities | ~£11.2bn net revenue |
What is included in the product
Primary Activities
In FY2025, Haleon's large global supply base made inbound logistics a control point: active ingredients, minerals, packaging, and other inputs must be checked at receipt before release to production. Tight incoming quality control matters because regulated oral health, pain relief, and vitamins products must stay consistent across high-volume batches. Faster, cleaner inbound flow lowers stock gaps and helps protect a revenue base of roughly £11bn.
In FY2025, Haleon's operations turned sourced inputs into tablets, capsules, oral-care products, and other consumer-health formats through tightly controlled manufacturing and packaging, with sales reaching over 100 markets. GMP discipline, batch traceability, and release testing protect product quality and brand trust. That matters because these repeat-buy products depend on steady output, low defect rates, and reliable shelf supply.
In FY2025, Haleon used warehouses, distributors, wholesalers, pharmacies, retailers, and e-commerce fulfillment to keep products near demand across 100+ markets. Strong outbound logistics supports shelf availability in fast-moving health categories and helps limit lost sales when stock turns quickly. This channel mix also fits Haleon's scale, with FY2025 sales of about £11 billion.
Marketing and Sales
Haleon creates value in FY2025 by turning brand trust into repeat buying across oral health, pain relief, respiratory, and digestive health. With net revenue near £11bn and products sold in 100+ markets, advertising, trade promo, retailer execution, and healthcare-professional influence matter most when shoppers choose at shelf. Strong marketing also supports premium pricing and helps protect share for names like Sensodyne, Panadol, and Voltaren.
Service
Haleon's service activity covers consumer support, product information, complaint handling, and adverse-event monitoring, which is vital for its health-led brands. In FY2025, this post-sale work helped protect compliance and trust by linking consumer feedback to safety reporting and quality checks. Digital content and pharmacist support also help people use Haleon products correctly, which lowers misuse risk and can reduce avoidable complaints.
In FY2025, Haleon's primary activities still centered on making and moving high-volume health products: inbound controls, GMP manufacturing, broad distribution, brand-led demand, and post-sale safety support. Net revenue was about £11bn, with sales in 100+ markets and names like Sensodyne, Panadol, and Voltaren doing most of the work.
| FY2025 | Key data |
|---|---|
| Net revenue | ~£11bn |
| Markets | 100+ |
| Core brands | Sensodyne, Panadol, Voltaren |
What You See Is What You Get
Haleon Reference Sources
This is the actual Haleon Value Chain Analysis document you'll receive upon purchase – no surprises, just the full professional version. The preview below is taken directly from the complete report, so what you see is exactly what you get. Once you buy, the full detailed Haleon Value Chain Analysis is unlocked immediately.
Frequently Asked Questions
Marketing and sales support Haleon's value chain most because the portfolio depends on trust, repeat purchase, and shelf presence in 4 major health needs. The company sells through pharmacies, retailers, and digital channels in 100+ markets, so brand spending and trade execution directly shape share. In OTC categories, awareness often drives conversion faster than price cuts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.